New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ruxolitinib phosphate 19.8mg equivalent to ruxolitinib 15 mg;   - tablet - 15 mg - active: ruxolitinib phosphate 19.8mg equivalent to ruxolitinib 15 mg   excipient: colloidal silicon dioxide hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium starch glycolate - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ruxolitinib phosphate 26.4mg equivalent to ruxolitinib 20 mg;   - tablet - 20 mg - active: ruxolitinib phosphate 26.4mg equivalent to ruxolitinib 20 mg   excipient: colloidal silicon dioxide hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium starch glycolate - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ruxolitinib phosphate 6.6mg equivalent to ruxolitinib 5 mg;   - tablet - 5 mg - active: ruxolitinib phosphate 6.6mg equivalent to ruxolitinib 5 mg   excipient: colloidal silicon dioxide hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium starch glycolate - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - apo-itraconazole indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ruxolitinib phosphate -

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ruxolitinib phosphate, quantity: 13.2 mg (equivalent: ruxolitinib, qty 10 mg) - tablet - excipient ingredients: hyprolose; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate type a - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.,jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.,jakavi is indicated for the treatment of patients aged 12 years and older with acute graft-versus-host disease who have inadequate response to corticosteroids.,jakavi is indicated for the treatment of patients aged 12 years and older with chronic graft-versus-host disease who have inadequate response to corticosteroids.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - mirabegron, quantity: 50 mg - tablet, modified release - excipient ingredients: macrogol 2000000; macrogol 8000; purified water; butylated hydroxytoluene; hyprolose; magnesium stearate; hypromellose; iron oxide yellow - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence in patients with overactive bladder (oab) syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - mirabegron, quantity: 25 mg - tablet, modified release - excipient ingredients: butylated hydroxytoluene; magnesium stearate; hyprolose; purified water; macrogol 2000000; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence in patients with overactive bladder (oab) syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ruxolitinib phosphate -

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ruxolitinib phosphate, quantity: 19.8 mg (equivalent: ruxolitinib, qty 15 mg) - tablet - excipient ingredients: povidone; microcrystalline cellulose; magnesium stearate; lactose monohydrate; sodium starch glycollate type a; colloidal anhydrous silica - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.,jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.,jakavi is indicated for the treatment of patients aged 12 years and older with acute graft-versus-host disease who have inadequate response to corticosteroids.,jakavi is indicated for the treatment of patients aged 12 years and older with chronic graft-versus-host disease who have inadequate response to corticosteroids.